KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income towards Common Stockholders: 2012-2024

Historic Net Income towards Common Stockholders for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$234.3 million.

  • Xenon Pharmaceuticals' Net Income towards Common Stockholders fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$234.3 million for FY2024, which is 28.48% down from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Net Income towards Common Stockholders is -$234.3 million, which was down 28.48% from -$182.4 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$28.0 million in FY2020 and a low of -$234.3 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$180.6 million, with a median of -$182.4 million in 2023.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Net Income towards Common Stockholders surged by 30.01% in 2020 and then crashed by 175.18% in 2021.
  • Over the past 5 years, Xenon Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$28.0 million in 2020, then tumbled by 175.18% to -$77.1 million in 2021, then slumped by 62.07% to -$124.9 million in 2022, then crashed by 45.99% to -$182.4 million in 2023, then fell by 28.48% to -$234.3 million in 2024.